Document is current
Any future updates will be listed below
-
Authors
Tumbo, Anneth-Mwasi
Schindler, Tobias
Dangy, Jean-Pierre
Orlova-Fink, Nina
Bieri, Jose Raso
Mpina, Maximillian
Milando, Florence A.
Juma, Omar
Hamad, Ali
Nyakarungu, Elizabeth
Chemba, Mwajuma
Mtoro, Ali
Ramadhan, Kamaka
Olotu, Ally
Makweba, Damas
Mgaya, Stephen
Stuart, Kenneth
Perreau, Matthieu
Stapleton, Jack T.
Jongo, Said
Hoffman, Stephen L.
Tanner, Marcel
Abdulla, Salim
Daubenberger, Claudia https://orcid.org/0000-0001-7136-0642
-
Funding
Funding for this research was provided by:
Swiss Government Excellence schorlaship (2016.056)
Equatorial Guinea Malaria Vaccine Initiative
Foundation for the National Institutes of Health (A1128194)
- License Information
-
More Information
Article History
Received: 24 August 2020
Accepted: 20 January 2021
First Online: 26 January 2021
Ethics approval and consent to participate
: The studies were registered at Clinicaltrial.gov. under the registration numbers NCT02132299 (BSPZV1), NCT02613520 (BSPZV2), NCT03420053 (BSPZV3a) and NCT02859350 (EGSPZV2). All clinical trials were approved by the Institutional Review Board for the Ifakara Health Institute (IHI-IRB), Tanzanian Food and Drug Administration (TFDA), Tanzanian National Institute for Medical Research (NIMR) and the Ethical Committee of Northern and Central Switzerland (EKNZ). Written informed consent was obtained from all participants prior enrolment. All trial procedures were conducted in accordance to good clinical practice (GCP) and under the Declaration of Helsinki.
: Not applicable.
: The authors declare that they have no competing interests.
